Clinical Trial Update: A Study to Test Different Doses of BI 1569912 in People With Depression [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of BI 1569912 in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• BI 1569912

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Depressive Disorder, Major | Phase 2 | Status: COMPLETED